Shares Of CellDex (CLDX) Breaking Out +16 Percent This Morning; Acadia BioPharma (ACAD) Continues To Surge
Good morning to all. Two stocks/companies that I have written about before many times on this blog, are both surging higher this morning, with CellDex (CLDX) enjoying a big morning so far, with shares up $3.55, or 16.7 percent to $24.62 on high volume — which is a good/bullish sign. Nearly 4M shares have been traded this morning already; and, average daily volume is about 2M. Traders and investors are clearly impressed with this news. The company announced ‘FDA Breakthrough Therapy Designation’ for its ninopepimt [drug] candidate for its treatment of adults with EGFRvlll-positive, gliobastoma tumors. This is great news for the company; and, should boost the stock price substantially higher, IMO I already own shares in the company; and, intend to add to my position this morning.
Meanwhile, shares of Acadia BioPharma (ACAD) are up 43 cents, or 1.16 percent to $37.88. Shares of ACAD gained 11 percent just last week, as speculation grows that the company may well get New Drug Approval from the FDA this year for its Pimavanserin Phase III drug for the treatment of Parkinson’s psychosis.
I added to my ACAD position last week; and am adding to my CLDX position this morning.
Remember, there are no guarantees. Do your own due diligence and homework. V/R, RCP